Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Autoimmune Disorders

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 90 articles: HTML format

Single Articles

June 2025
1. WOLFE GI, Shelly S
   Myasthenia Gravis - Redemption for B-Cell Depletion.
   N Engl J Med. 2025;392:2382-2384.
   PubMed    
   
   
   
2. ZHANG L, Gao Z, Pan H, Li R, et al
   BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy.
   N Engl J Med. 2025;392:2282-2284.
   PubMed    
   
   
   May 2025
3. KOSTER MJ, Warrington KJ
   Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis.
   N Engl J Med. 2025;392:2062-2064.
   PubMed    
   
   
   
4. BARRATT J, Perkovic V, Rizk DV
   Alternative Complement Pathway, Iptacopan, and IgA Nephropathy. Reply.
   N Engl J Med. 2025;392:1976.
   PubMed    
   
   
   
5. ANGELETTI A, Marasa M, Cravedi P
   Alternative Complement Pathway, Iptacopan, and IgA Nephropathy.
   N Engl J Med. 2025;392:1976.
   PubMed    
   
   
   
6. POPPELAARS F, Faria B, Thurman JM
   Alternative Complement Pathway, Iptacopan, and IgA Nephropathy.
   N Engl J Med. 2025;392:1975.
   PubMed    
   
   
   
7. CALABRESI PA
   Progress toward Mitigating Disability Progression in Multiple Sclerosis.
   N Engl J Med. 2025;392:1966-1968.
   PubMed    
   
   
   
8. HOSHINO Y, Okamoto K, Ito N
   More on Acquired Osteomalacia and Autoantibodies against PHEX. Reply.
   N Engl J Med. 2025;392:1871-1872.
   PubMed    
   
   
   
9. MINISOLA S, Pepe J, Cipriani C
   More on Acquired Osteomalacia and Autoantibodies against PHEX.
   N Engl J Med. 2025;392:1871.
   PubMed    
   
   
   April 2025
10. FAVA A
    To B or Not to B - the Role of B-Cell Depletion in Lupus Nephritis.
    N Engl J Med. 2025;392:1545-1547.
    PubMed    
    
    
    
11. FOX RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, et al
    Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.
    N Engl J Med. 2025 Apr 8. doi: 10.1056/NEJMoa2415988.
    PubMed     Abstract available
    
    
    
12. OH J, Arnold DL, Cree BAC, Ionete C, et al
    Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
    N Engl J Med. 2025 Apr 8. doi: 10.1056/NEJMoa2415985.
    PubMed     Abstract available
    
    
    
13. NOWAK RJ, Benatar M, Ciafaloni E, Howard JF Jr, et al
    A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
    N Engl J Med. 2025 Apr 8. doi: 10.1056/NEJMoa2501561.
    PubMed     Abstract available
    
    
    
14. BLOCKMANS D, Penn SK, Setty AR, Schmidt WA, et al
    A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.
    N Engl J Med. 2025 Apr 2. doi: 10.1056/NEJMoa2413449.
    PubMed     Abstract available
    
    
    March 2025
15. STONE JH, Khosroshahi A, Zhang W, Della Torre E, et al
    Inebilizumab for Treatment of IgG4-Related Disease.
    N Engl J Med. 2025;392:1168-1177.
    PubMed     Abstract available
    
    
    February 2025
16. WANG JJ, Warkentin TE, Schonborn L, Wheeler MB, et al
    VITT-like Monoclonal Gammopathy of Thrombotic Significance.
    N Engl J Med. 2025 Feb 12. doi: 10.1056/NEJMoa2415930.
    PubMed     Abstract available
    
    
    
17. FURIE RA, Rovin BH, Garg JP, Santiago MB, et al
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025 Feb 7. doi: 10.1056/NEJMoa2410965.
    PubMed     Abstract available
    
    
    January 2025
18. HOSHINO Y, Okamoto K, Ogawa T, Kato H, et al
    Acquired Osteomalacia Associated with Autoantibodies against PHEX.
    N Engl J Med. 2025;392:513-515.
    PubMed    
    
    
    October 2024
19. PERKOVIC V, Barratt J, Rovin B, Kashihara N, et al
    Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.
    N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMoa2410316.
    PubMed     Abstract available
    
    
    
20. INGELFINGER JR
    Way Stations in Progress - Burgeoning Treatment Options for IgA Nephropathy.
    N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMe2413288.
    PubMed    
    
    
    
21. HEERSPINK HJL, Jardine M, Kohan DE, Lafayette RA, et al
    Atrasentan in Patients with IgA Nephropathy.
    N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMoa2409415.
    PubMed     Abstract available
    
    
    
22. CHANTRAPITAK J, Chuamanochan M
    Intertriginous Rash in Secondary Syphilis.
    N Engl J Med. 2024;391:e28.
    PubMed    
    
    
    
23. TOMAS NM, Hengel FE, Huber TB
    Autoantibodies Targeting Nephrin in Podocytopathies. Reply.
    N Engl J Med. 2024;391:1367-1368.
    PubMed    
    
    
    
24. BRUSCHI M, Angeletti A, Ghiggeri GM
    Autoantibodies Targeting Nephrin in Podocytopathies.
    N Engl J Med. 2024;391:1366.
    PubMed    
    
    
    
25. BERG AH, Karumanchi SA
    Autoantibodies Targeting Nephrin in Podocytopathies.
    N Engl J Med. 2024;391:1365-1366.
    PubMed    
    
    
    
26. GLEESON PJ, Monteiro RC
    Autoantibodies Targeting Nephrin in Podocytopathies.
    N Engl J Med. 2024;391:1365.
    PubMed    
    
    
    September 2024
27. RUSSO G, Alipour Tehrany Y
    Discoid Lupus Erythematosus.
    N Engl J Med. 2024;391:e24.
    PubMed    
    
    
    
28. SALVARANI C, Hunder GG, Brown RD Jr
    Primary Central Nervous System Vasculitis.
    N Engl J Med. 2024;391:1028-1037.
    PubMed    
    
    
    
29. HAGEN M, Bucci L, Boltz S, Nothling DM, et al
    BCMA-Targeted T-Cell-Engager Therapy for Autoimmune Disease.
    N Engl J Med. 2024;391:867-869.
    PubMed    
    
    
    
30. ALEXANDER T, Kronke J, Cheng Q, Keller U, et al
    Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus.
    N Engl J Med. 2024;391:864-866.
    PubMed    
    
    
    August 2024
31. GRIFFIN H, Ceron-Gutierrez L, Gharahdaghi N, Ebrahimi S, et al
    Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease.
    N Engl J Med. 2024;391:434-441.
    PubMed     Abstract available
    
    
    July 2024
32. LI M, Zhang Y, Jiang N, Ning C, et al
    Anti-CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE.
    N Engl J Med. 2024;391:376-378.
    PubMed    
    
    
    
33. WANG WY, Lin MC
    Chilblain Lupus Erythematosus.
    N Engl J Med. 2024;391:e6.
    PubMed    
    
    
    
34. CHENG A, Holland SM
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency. Reply.
    N Engl J Med. 2024;391:189-190.
    PubMed    
    
    
    
35. ROSMARIN D, Amara S, Lebwohl M
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;391:189.
    PubMed    
    
    
    
36. COHEN JM, Damsky W
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;391:188-189.
    PubMed    
    
    
    
37. FEREDJ E, Cobat A, Casanova JL
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;391:187-188.
    PubMed    
    
    
    June 2024
38. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:2227.
    PubMed    
    
    
    
39. MAAHS DM, Svensson J
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226-2227.
    PubMed    
    
    
    
40. WENSTEDT EFE, Vogt L
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226.
    PubMed    
    
    
    
41. CHEN Y, Xu Y, Li H, Sun T, et al
    A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia.
    N Engl J Med. 2024;390:2178-2190.
    PubMed     Abstract available
    
    
    May 2024
42. WECHSLER ME, Fan Y, Merkel PA
    Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. Reply.
    N Engl J Med. 2024;390:1940.
    PubMed    
    
    
    
43. SUN R, Wei LJ
    Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
    N Engl J Med. 2024;390:1939.
    PubMed    
    
    
    
44. OIKONOMOU V, Smith G, Constantine GM, Schmitt MM, et al
    The Role of Interferon-gamma in Autoimmune Polyendocrine Syndrome Type 1.
    N Engl J Med. 2024;390:1873-1884.
    PubMed     Abstract available
    
    
    
45. SU MA
    JAK Inhibition Immunotherapy for APS-1.
    N Engl J Med. 2024;390:1918-1921.
    PubMed    
    
    
    
46. HENGEL FE, Dehde S, Lasse M, Zahner G, et al
    Autoantibodies Targeting Nephrin in Podocytopathies.
    N Engl J Med. 2024 May 25. doi: 10.1056/NEJMoa2314471.
    PubMed     Abstract available
    
    
    
47. WANG JJ, Schonborn L, Warkentin TE, Chataway T, et al
    Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders.
    N Engl J Med. 2024;390:1827-1829.
    PubMed    
    
    
    
48. DOUGHTY CT, Schaefer PW, Brizzi K, Linnoila JJ, et al
    Case 14-2024: A 30-Year-Old Woman with Back Pain, Leg Stiffness, and Falls.
    N Engl J Med. 2024;390:1712-1719.
    PubMed    
    
    
    
49. MULLER F, Mackensen A, Schett G
    CAR T-Cell Therapy in Autoimmune Disease. Reply.
    N Engl J Med. 2024;390:1631-1632.
    PubMed    
    
    
    
50. HOWARD JF JR, Vu T, Mozaffar T
    CAR T-Cell Therapy in Autoimmune Disease.
    N Engl J Med. 2024;390:1629-1631.
    PubMed    
    
    
    
51. DE BENEDETTI F, Diomedi Camassei F, Locatelli F
    CAR T-Cell Therapy in Autoimmune Disease.
    N Engl J Med. 2024;390:1629.
    PubMed    
    
    
    
52. MERKT W, Lorenz HM, Schmitt M
    CAR T-Cell Therapy in Autoimmune Disease.
    N Engl J Med. 2024;390:1628-1629.
    PubMed    
    
    
    April 2024
53. MATHUR M, Barratt J, Suzuki Y
    Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. Reply.
    N Engl J Med. 2024;390:1245-1246.
    PubMed    
    
    
    
54. BELMONT HM
    Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
    N Engl J Med. 2024;390:1245.
    PubMed    
    
    
    
55. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:1207-1217.
    PubMed    
    
    
    March 2024
56. NETEA MG, van de Veerdonk FL
    Anti-Interleukin-23 Autoantibodies and Severe Infections.
    N Engl J Med. 2024;390:1143-1146.
    PubMed    
    
    
    
57. CHENG A, Kashyap A, Salvator H, Rosen LB, et al
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;390:1105-1117.
    PubMed     Abstract available
    
    
    
58. DRIVENES JL, Bygum A
    Spontaneous Oral Purpura in Immune Thrombocytopenia.
    N Engl J Med. 2024;390:1029.
    PubMed    
    
    
    
59. WECHSLER ME, Nair P, Terrier B, Walz B, et al
    Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
    N Engl J Med. 2024;390:911-921.
    PubMed     Abstract available
    
    
    February 2024
60. MULLER F, Taubmann J, Bucci L, Wilhelm A, et al
    CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
    N Engl J Med. 2024;390:687-700.
    PubMed     Abstract available
    
    
    
61. ISAACS JD
    CAR T Cells - A New Horizon for Autoimmunity?
    N Engl J Med. 2024;390:758-759.
    PubMed    
    
    
    
62. HAUSER SL
    Silencing Immune Dialogue in Multiple Sclerosis.
    N Engl J Med. 2024;390:662-663.
    PubMed    
    
    
    
63. VERMERSCH P, Granziera C, Mao-Draayer Y, Cutter G, et al
    Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
    N Engl J Med. 2024;390:589-600.
    PubMed     Abstract available
    
    
    January 2024
64. DANDONA P, Chaudhuri A, Ghanim H
    More on Semaglutide in Early Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:292.
    PubMed    
    
    
    
65. GAGLIA JL, Laffel LM, Patti ME
    More on Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2024;390:291.
    PubMed    
    
    
    
66. WEINRAUCH LA, D'Elia JA
    More on Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2024;390:291.
    PubMed    
    
    
    
67. DEVRIES JH
    More on Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2024;390:290.
    PubMed    
    
    
    
68. HADZIC N, Deheragoda M, Worth A, Bansal S, et al
    JAK Inhibition in STAT1 Gain-of-Function-Mediated Treatment-Resistant Autoimmune Hepatitis.
    N Engl J Med. 2024;390:284-286.
    PubMed    
    
    
    
69. LEE TTM, Bergford S, Murphy HR
    Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:184.
    PubMed    
    
    
    
70. GRZYCH G, Kim I
    Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes.
    N Engl J Med. 2024;390:183-184.
    PubMed    
    
    
    
71. VIVANTI AJ, Benachi A, Voican A
    Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes.
    N Engl J Med. 2024;390:183.
    PubMed    
    
    
    
72. LEMLEY KV, Glassock RJ
    APRIL - Springtime for New IgA Nephropathy Therapy?
    N Engl J Med. 2024;390:80-81.
    PubMed    
    
    
    
73. LIU MJ, Li J
    Necrobiosis Lipoidica.
    N Engl J Med. 2024;390:70.
    PubMed    
    
    
    December 2023
74. ARJUNAN D, Bhadada SK
    Thyroid Dermopathy in Graves' Disease.
    N Engl J Med. 2023;389:2376.
    PubMed    
    
    
    
75. LUDVIGSSON J
    Immune Interventions at Onset of Type 1 Diabetes - Finally, a Bit of Hope.
    N Engl J Med. 2023;389:2199-2201.
    PubMed    
    
    
    
76. WAIBEL M, Wentworth JM, So M, Couper JJ, et al
    Baricitinib and beta-Cell Function in Patients with New-Onset Type 1 Diabetes.
    N Engl J Med. 2023;389:2140-2150.
    PubMed     Abstract available
    
    
    November 2023
77. EL-ZAATARI ZM
    Anti-Glomerular Basement Membrane Glomerulonephritis.
    N Engl J Med. 2023;389:1901.
    PubMed    
    
    
    
78. BUSSEL JB, Hou M, Cines DB
    Primary Immune Thrombocytopenia in Pregnancy. Reply.
    N Engl J Med. 2023;389:1728.
    PubMed    
    
    
    
79. TRAN BW, May KA, Pal N
    Primary Immune Thrombocytopenia in Pregnancy.
    N Engl J Med. 2023;389:1728.
    PubMed    
    
    
    
80. MATHUR M, Barratt J, Chacko B, Chan TM, et al
    A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
    N Engl J Med. 2023 Nov 2. doi: 10.1056/NEJMoa2305635.
    PubMed     Abstract available
    
    
    October 2023
81. RAMOS EL, Dayan CM, Chatenoud L, Sumnik Z, et al
    Teplizumab and beta-Cell Function in Newly Diagnosed Type 1 Diabetes.
    N Engl J Med. 2023 Oct 18. doi: 10.1056/NEJMoa2308743.
    PubMed     Abstract available
    
    
    
82. LINDHOFF-LAST E, Schonborn L, Zaninetti C, Warkentin TE, et al
    Rescue Therapy in Chronic Prothrombotic Autoimmune Anti-PF4 Disorder.
    N Engl J Med. 2023;389:1339-1341.
    PubMed    
    
    
    
83. SPIERA RF, Unizony S, Warrington KJ, Sloane J, et al
    Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
    N Engl J Med. 2023;389:1263-1272.
    PubMed     Abstract available
    
    
    
84. LEE TTM, Collett C, Bergford S, Hartnell S, et al
    Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes.
    N Engl J Med. 2023 Oct 5. doi: 10.1056/NEJMoa2303911.
    PubMed     Abstract available
    
    
    
85. GARG SK, Polsky S
    Technology Use and Glycemic Outcomes during Pregnancy with Type 1 Diabetes.
    N Engl J Med. 2023 Oct 5. doi: 10.1056/NEJMe2310798.
    PubMed    
    
    
    
86. ALETAHA D
    Polymyalgia Rheumatica - from Search for Efficacy to Choice of Strategy.
    N Engl J Med. 2023;389:1328-1329.
    PubMed    
    
    
    September 2023
87. BRODERICK L, Kastner DL
    Variant STAT4 and Treatment of an Autoinflammatory Syndrome. Reply.
    N Engl J Med. 2023;389:1151-1152.
    PubMed    
    
    
    
88. PASTORE S, De Martino E, Taddio A
    Variant STAT4 and Treatment of an Autoinflammatory Syndrome.
    N Engl J Med. 2023;389:1151.
    PubMed    
    
    
    
89. WANG WY, Cheng ST
    Sleeve Sign and Inverse Gottron's Papules in Anti-MDA5 Dermatomyositis.
    N Engl J Med. 2023;389:1032.
    PubMed    
    
    
    
90. DANDONA P, Chaudhuri A, Ghanim H
    Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2023;389:958-959.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.